Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Zinecard

(dexrazoxane hydrochloride)

Phase 3Small molecule

CChildren's Oncology Group

Dexrazoxane is used to protect the heart from damage caused by certain chemotherapy drugs (called anthracyclines) that are used to treat cancer, and to treat iron overload in the body.[1] Zinecard is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]

Zinecard is one of 270 small molecule programs targeting Anaplastic Large Cell Lymphoma. It is currently in Phase 3.

9

Indications

23

Total Trials

5

Active Trials

269

Competitors

Pipeline

Status by Indication[3][1]

Indication

Anaplastic Large Cell LymphomaActive, not recruiting

CardiomyopathyUnknown

OsteosarcomaActive, not recruiting

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Breast CancerUnknown

Soft Tissue SarcomaActive, not recruiting

RhabdomyosarcomaActive, not recruiting

Anaplastic Large Cell LymphomaPhase 1

Active, not recruiting

CardiomyopathyPreclinical

Unknown

OsteosarcomaPhase 2

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

NeuroblastomaPhase 3

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 3

Active, not recruiting

Breast CancerPreclinical

Unknown

Soft Tissue SarcomaPhase 2

Active, not recruiting

RhabdomyosarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Zinecard

CChildren's Oncology Group

Trodelvy

Tecentriq

Cymbalta

Alnylam Pharmaceuticals

Zolymbus

MS Contin

HHikma Pharmaceuticals LLC

Acupan

YYonsei University

Chirocaine

PPurdue Pharma LP

Chantix

PPrism Pharmaceuticals

Paracetamol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT00077285

Q3 2027

Phase 3Active, not recruiting

Acute Lymphoblastic Leukemia

NCT03007147

Q4 2027

Phase 2Recruiting

Effects of Chemotherapy

NCT03589729

Q2 2029

Phase 3Recruiting

Newly Diagnosed

NCT04293562

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia4 trials

Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma

Completed·CChildren's Oncology Group·Phase 3·NCT01230983·573 enrolled

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Completed·—·Phase 3·NCT00400946·800 enrolled

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed·CChildren's Oncology Group·Phase 1/2·NCT00098839·134 enrolled

Show 1 more trial

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03007147·475 enrolled

Osteosarcoma3 trials

Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma

Completed·CChildren's Oncology Group·Phase 1·NCT00742924·24 enrolled

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00019864·100 enrolled

Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00003937·253 enrolled

Hodgkin's Disease2 trials

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00005578·219 enrolled

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00002827·294 enrolled

Breast Cancer2 trials

Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer

Terminated·FFudan University·Phase 2·NCT00955890·12 enrolled

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00016276·396 enrolled

Newly Diagnosed2 trials

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Recruiting·CChildren's Oncology Group·Phase 3·NCT04293562·1,186 enrolled

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Withdrawn·CChildren's Oncology Group·Phase 3·NCT00334867

10 more indications

Refractory Solid Tumors1 trial

Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00039481·15 enrolled

Anaplastic Large Cell Lymphoma1 trial

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Completed·CChildren's Oncology Group·Phase 1·NCT01606878·46 enrolled

Patients With Advanced Solid Tumors1 trial

Dexrazoxane and Cisplatin in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00550901·25 enrolled

Neuroblastoma1 trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Recruiting·CChildren's Oncology Group·Phase 3·NCT03126916·750 enrolled

Biological Therapy1 trial

Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003667

Rhabdomyosarcoma1 trial

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00077285·65 enrolled

Soft Tissue Sarcoma1 trial

Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma

Terminated·—·Phase 2·NCT00544778·7 enrolled

Leukemia1 trial

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00933985·22 enrolled

Effects of Chemotherapy1 trial

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03589729·100 enrolled

Radiation Therapy1 trial

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

Completed·—·Phase 2·NCT00084838·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for dexrazoxane hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — dexrazoxane hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for dexrazoxane hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Children's Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CChildren's Oncology Group

Related News